In subjects with severe T2 eosinophilic phenotype asthma, the presence of comorbidities affecting the upper airways increases as peripheral eosinophilia increases and, therefore, patients with these characteristics may benefit more from treatment with IL-5/Rα, even if the anti-IL-4/13 and anti-IgE treatment are recommended as first-line treatments in these patients. The gene discussed is IL5; the disease is asthma.